|
|
|
| A case of severe chronic renal tubular-interstitial injury induced by Cyclosporin A |
| WU Huiyi1 PAN Yuhua2 LAO Haiyan2 |
1.Department of Pharmacy, Nanfang Hospital of Southern Medical University, Guangdong Province, Guangzhou 510515, China;
2.Department of Pharmacy, Guangdong General Hospital, Guangdong Province, Guangzhou 510080, China |
|
|
|
Abstract One patient with membranous nephropathy used Cyclosporin A and low dose of glucocorticoid for treatment, after continuous medication, the patient′s serum creatinine and blood pressure progressively increased. The pathological changes after repeated kidney biopsy suggested the phase Ⅲ membranous nephropathy associated with severe chronic renal tubular-interstitial injury. In combination with medical history, clinical manifestations, laboratory and pathological examination, excluding other factors, Cyclosporin A is considered to be the main contributor to irreversible chronic renal tubule-interstitial injury. By analyzing and summarizing of the case, chronic renal toxicity is the obvious side effect of Cyclosporin A. Although the renal toxicity depends on the dose or concentration of Cyclosporin A, it can still happen when the plasma concentration in the normal range of treatment. Therefore, clinicians should attach great importance to the use of Cyclosporin A, fully grasp its relevant knowledge, prevent early and interfere timely to Cyclosporin A related nephrotoxicity, reducing the risk and harm.
|
|
|
|
|
|
[1] 中国成人肾病综合征免疫抑制治疗专家组.中国成人肾病综合征免疫抑制治疗专家共识[J].中华肾脏病杂志，2014，30（6）：467-474.
[2] 《环孢素A在肾内科的应用》专家协作组.环孢素A治疗肾小球疾病的应用共识[J].中华肾脏病杂志，2005，21（9）：556-557.
[3] 尹智峰，王毅，秦国庆.环孢素致慢性肾毒性研究进展[J].现代生物医学进展，2009，9（22）：4368-4370.
[4] Shah SR，Altaf A，Arshad MH，et al. Use of cyclosporine therapy in steroid resistant nephrotic syndrome（SRNS）：a review [J]. Glob J Health Sci，2015，8（4）：136-141.
[5] 陈嘉薇.环孢素A毒性机制的研究进展[J].中华器官移植杂志，2003，24（4）：255-256.
[6] 王海燕.肾脏病学[M].3版.北京：人民卫生出版社，2008：1170.
[7] 杨静，董艺宁，彭婷婷，等.环孢素A与钙离子通道拮抗剂的相互作用及临床意义[J].中国现代应用药学，2015， 32（7）：891-894.
[8] 廖秀娟，韦柳萍.环孢素A的药动学及其影响因素研究进展[J].中国药房，2015，26（4） ：558-561．
[9] Xue W，Ding X，Tian P，et al． Long-term follow-up of co-administration of diltiazem and cyclosporine in Chinese kidney transplant recipients [J]. Ren Fail，2010，32（3）：314-319.
[10] 劳海燕，刘双信，马建超，等.环孢素对肾病综合征患者血清肌酐水平的影响[J].药物不良反应杂志，2016，18（1）：15-18.
[11] 刘奕明，林爱华，邓时贵，等.环孢素A诱导的大鼠慢性肾毒性变化及与血药浓度的关系[J].广东医学，2009， 30（1）：29-30.
[12] 潘铁军，唐礼功，文瀚东，等.环孢素A移植肾毒性损害的病理变化[J].中华泌尿外科杂志，2003，24（3）：178-179.
[13] 张维明，李克儒.环孢素的肾毒性及防治研究进展[J].国外医学：泌尿系统分册，2000，20（1）：19-21.
[14] Sánchez-Lozada LG，Tapia E，Rodríguez-Iturbe B，et al. Hemodynamics of hyperuricemia [J]. Semin Nephrol，2005， 25（1）：19-24.
[15] 王沛，刘章锁，骆红，等.长期应用环孢素A致大鼠肾脏病变演变过程观察[J].郑州大学学报，2007，42（6）：1044-1048.
[16] Regeniter A，Freidank H，Dickenmann M，et al. Evaluation of proteinuria and GFR to diagnose and classify kidney disease：systematic review and proof of concept [J]. Eur J Intern Med，2009，20（6）：556-561.
[17] Comper WD，Hilliard LM，Nikolic-Paterson DJ，et al. Disease dependent mechanisms of albuminuria [J]. Am J Physiol Renal Physiol，2008，295（6）：F1589-F1600.
[18] 刘俊，陈香美.蛋白尿加速肾小管损伤的作用机制[J].中华肾病研究电子杂志，2014，3（2）：99-102.
[19] 邓洪.蛋白尿对肾间质纤维化的影响[D].长沙：中南大学，2007.
[20] Lazarus B，Chen Y，Wilson FP，et al. Proton pump inhibitor use and risk of chronic kidney disease [J]. JAMA Intern Med，2016，176（2）：238-246.
[21] Klatte DCF，Gasparini A，Xu H，et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease [J]. Gastroenterology，2017，153（3）：702-710.
[22] Xie Y，Bowe B，Li T，et al. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD [J]. J Am Soc Nephrol，2016，27（10）：3153-3163.
[23] Yoon HE，Yang CW. Established and newly proposed mechanisms of chronic cyclosporine nephropathy [J]. Korean J Intern Med，2009，24（2）：81-92. |
|
|
|
